Mehta Rashmi, Piscitelli Joseph, Wolstenholme Allen, Fu Caifeng, Crauwels Herta, Wynne Brian, Adkison Kimberly
GlaxoSmithKline, Research Triangle Park, NC, USA.
UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA.
Clin Pharmacol. 2020 Jun 8;12:49-52. doi: 10.2147/CPAA.S250751. eCollection 2020.
Dolutegravir 50 mg (DTG) and rilpivirine 25 mg (RPV) are a newly approved 2-drug regimen for the treatment of HIV in virally suppressed patients. A 2-part study evaluated the relative bioavailability and food effect of five experimental fixed-dose combination (FDC) tablet formulations of DTG/RPV. When given with a moderate- or high-fat meal, the absorption of both DTG and RPV was increased, resulting in higher exposures. As per product labelling, DTG/RPV FDC should be taken with a meal.
多替拉韦50毫克（DTG）和利匹韦林25毫克（RPV）是一种新批准的用于治疗病毒得到抑制的HIV患者的双药方案。一项分为两部分的研究评估了DTG/RPV五种实验性固定剂量复方（FDC）片剂配方的相对生物利用度和食物影响。与中脂或高脂餐同服时，DTG和RPV的吸收均增加，导致更高的暴露量。根据产品标签，DTG/RPV FDC应与食物同服。
